AG
RNTX

Advisor Group’s Rein Therapeutics RNTX Stock Holding History

Advisor Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8
Closed – – 5472
2019
Q3 		$0 Hold
8
– – ﹤0.01% 5456
2019
Q2 		$0 Hold
8
– – ﹤0.01% 5383
2019
Q1 		$0 Hold
8
– – ﹤0.01% 5357
2018
Q4 		$0 Hold
8
– – ﹤0.01% 5266
2018
Q3 		$0 Hold
8
– – ﹤0.01% 5246
2018
Q2 		$1K Hold
8
– – ﹤0.01% 4846
2018
Q1 		$1K Hold
8
– – ﹤0.01% 4868
2017
Q4 		$2K Buy
+8
New +$1.92K ﹤0.01% 4725

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $16.1B AUM 40.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
IWAG
Integer Wealth Advisors Group Cartersville, Georgia $184M AUM 62.15% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $692M AUM 32% 1-Year Est. Return

Advisor Group's RNTX Position: Q4 2019 in Review

Advisor Group sold out of Rein Therapeutics (RNTX) in Q4 2019, closing a stake of 8 shares.

Advisor Group first reported a position in RNTX in Q4 2017 and held it in 8 quarters. The position peaked at $2K in Q4 2017. 17 funds tracked by Wall St. Rank hold RNTX as of Q4 2019.

  • Advisor Group reported no remaining Rein Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Advisor Group sold 8 Rein Therapeutics shares in Q4 2019.
  • Advisor Group first reported a position in Rein Therapeutics in Q4 2017 and held it in 8 quarters.
  • Advisor Group's Rein Therapeutics position peaked at $2K in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.